Endpoints for diuresis: Are we there yet?

Muthiah Vaduganathan; Stephen J. Greene; Javed Butler; Mihai Gheorghiade

doi:10.1016/j.jacc.2013.04.108

Endpoints for diuresis: Are we there yet?

Muthiah Vaduganathan, Stephen J. Greene, Javed Butler, Mihai Gheorghiade^*

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	838-839
Number of pages	2
Journal	Journal of the American College of Cardiology
Volume	63
Issue number	8
DOIs	https://doi.org/10.1016/j.jacc.2013.04.108
State	Published - Mar 4 2014

Funding

Please note: Dr. Gheorghiade has served as consultant to Abbott Laboratories, Astellas, AstraZeneca, Bayer Schering Pharma AG, CorThera, Inc., Cytokinetics, Inc., DebioPharm SA, Errekappa Terapeutici, GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck, Novartis Pharma AG, Otsuka Pharmaceuticals, Pericor Therapeutics, Protein Design Laboratories, Sanofi-Aventis, Sigma Tau, and Solvay Pharmaceuticals. Dr. Butler has received research funding from the NIH, EU, Health Resource Services Administration, and the Food and Drug Administration; and has consulting relationships with Amgen, Bayer, BG Medicine, Cardiocell, Celladon, Covis, Gambro, GE Healthcare, Janssen, Medtronic, Novartis, Ono Pharmaceutical, Relypsa, Trevena, and Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacc.2013.04.108

Cite this

@article{fe6744f084e241a69121fbf55e5b1973,

title = "Endpoints for diuresis: Are we there yet?",

author = "Muthiah Vaduganathan and Greene, {Stephen J.} and Javed Butler and Mihai Gheorghiade",

note = "Funding Information: Please note: Dr. Gheorghiade has served as consultant to Abbott Laboratories, Astellas, AstraZeneca, Bayer Schering Pharma AG, CorThera, Inc., Cytokinetics, Inc., DebioPharm SA, Errekappa Terapeutici, GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck, Novartis Pharma AG, Otsuka Pharmaceuticals, Pericor Therapeutics, Protein Design Laboratories, Sanofi-Aventis, Sigma Tau, and Solvay Pharmaceuticals. Dr. Butler has received research funding from the NIH, EU, Health Resource Services Administration, and the Food and Drug Administration; and has consulting relationships with Amgen, Bayer, BG Medicine, Cardiocell, Celladon, Covis, Gambro, GE Healthcare, Janssen, Medtronic, Novartis, Ono Pharmaceutical, Relypsa, Trevena, and Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. ",

year = "2014",

month = mar,

day = "4",

doi = "10.1016/j.jacc.2013.04.108",

language = "English (US)",

volume = "63",

pages = "838--839",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier Inc.",

number = "8",

}

TY - JOUR

T1 - Endpoints for diuresis

T2 - Are we there yet?

AU - Vaduganathan, Muthiah

AU - Greene, Stephen J.

AU - Butler, Javed

AU - Gheorghiade, Mihai

N1 - Funding Information: Please note: Dr. Gheorghiade has served as consultant to Abbott Laboratories, Astellas, AstraZeneca, Bayer Schering Pharma AG, CorThera, Inc., Cytokinetics, Inc., DebioPharm SA, Errekappa Terapeutici, GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck, Novartis Pharma AG, Otsuka Pharmaceuticals, Pericor Therapeutics, Protein Design Laboratories, Sanofi-Aventis, Sigma Tau, and Solvay Pharmaceuticals. Dr. Butler has received research funding from the NIH, EU, Health Resource Services Administration, and the Food and Drug Administration; and has consulting relationships with Amgen, Bayer, BG Medicine, Cardiocell, Celladon, Covis, Gambro, GE Healthcare, Janssen, Medtronic, Novartis, Ono Pharmaceutical, Relypsa, Trevena, and Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2014/3/4

Y1 - 2014/3/4

UR - http://www.scopus.com/inward/record.url?scp=84896727659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896727659&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2013.04.108

DO - 10.1016/j.jacc.2013.04.108

M3 - Letter

C2 - 24315896

AN - SCOPUS:84896727659

SN - 0735-1097

VL - 63

SP - 838

EP - 839

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 8

ER -

Endpoints for diuresis: Are we there yet?

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this